Team : Cell Plasticity and Cancer


To extend Pink October, breast cancer awareness month, here are the interviews with Prof. Adriaenssens and Dr. Lagadec, of the “Cellular Plasticity and Cancer” from Canther UMR, broadcast on Radio Campus Lille, on Wednesday October 14, exposing their research fields and demonstrating their efforts and commitments in research against these diseases.

Prof. Adriaenssens interview:

Dr. Lagadec interview:

Our team brings together researchers, professors, associate professors, clinicians, technicians and students. Our common goal is to decipher molecular mechanisms of cancer cell plasticity which govern resistance to therapies in breast cancer and pediatric gliomas.

Historically located at the Faculty of Sciences and Technology campus in Villeneuve d’Ascq, our team is located at two sites since the welcoming of a team from Oscar Lambret Center (COL) in 2015: the Faculty of Science and Technology of Lille University and the Lille Institute for Cancer Research (IRCL) at the Lille hospital campus.

Since its creation in 2008, our team is continuously increasing its field of expertise.  We have welcomed members developing new approaches in molecular and cellular biology, epigenetics and computational biology. Physicians from COL and CHR also allow us to access to samples and cells from patients for translational research; some equipment such as the COL radiotherapy platform is at our disposal to investigate mechanisms of radiotherapy-induced resistance of breast cancer and pediatric gliomas.

Our project benefits from the complementary and well recognized competences of the team members, including proteomics and epigenomics, the study of cancer stem cells reprogramming, in vivo transgenic mouse and zebrafish models, artificial intelligence in oncogenomics and cellular regulatory networks. In collaboration with physicists from the LIMMS unit and IEMN, we have developed MicroEctroMechanical (MEMS) to characterize the mechanical properties of individual cells, as well as a microfluidic system to characterize disseminated breast cancer cells and their potential plasticity in tumor dormancy/metastasis. In addition to local interactions with different teams in Lille, our team has developed national, european and international collaborations.

Through this fundamental and translational research, our final objective is to discover new markers and / or therapeutic targets, and to propose innovative therapeutic strategies for the treatment of breast cancer and childhood gliomas.



Pr Xuefen LE BOURHIS, University of Lille
Research field: Molecular mechanisms of cancer cell plasticity governing tumor resistance to therapies and metastasis formation.
Key words: Cell plasticity, tumor resistance, metastasis, microenvironment, signaling, epigenetics.


Pr Eric ADRIAENSSENS, University of Lille
Research field:
Role and mechanisms of action of long non coding  RNA H19 in breast cancer.
Key words: H19, LncRNA, breast cancer, microRNA, genetic instability, metastasis.


Pr Pierre-Olivier ANGRAND, University of Lille
Research field: Epigenetics and zebrafish model in cancerology.
Key words: Zebrafish, epigenetics, histones, polycomb repression, genome editing, transgenesis, xenotransplantation.


Dr Roland BOURETTE, Researcher CRCN CNRS
Research field: Study of breast cancer stem cells.
Key words: Stem cells, transgenic mice, development, signaling, s‑SHIP.


Dr Valérie CHOPIN, Associate Professor, University of Picardie Jules Verne
Research field:
Mechanisms of the resistance to therapies.
Key words: Cell plasticity, tumor resistance, signaling.


Dr Wajdi DHIFLI, Associate Professor, University of Lille
Research field: Inference, Interrogation and Engineering of regulatory networks.
Key words: Systems biology, bio-informatics, automatic learning and  artificial intelligence.


Pr Mohamed ELATI, University of Lille
Research field: Inference, Interrogation and Engineering of regulatory networks.
Key words: Systems biology, bio-informatics, automatic learning and  artificial intelligence.


Dr Alessandro FURLAN, Postdoctoral Researcher, Centre Oscar Lambret
Research field: Development of a 3D model on microfluidic chip for the study of DIPG.
Key words: DIPG, pediatric glioma, tumor-on-a-chip, BBB, microscopy.


Pr Robert-Alain TOILLON, University of Lille
Research field: Study of TrkA-induced receptors complexes in breast cancer resistance to therapies and metastasis.
Key words: Neurotrophins, TrkA, tyrosine kinase, resistance to drugs, signaling, breast cancer, metastasis.

Web of Science Researcher ID: Q-2286-2018
GdR APPICOM. “Approches intégratives pour l’étude des protéines membranaires”.


Dr Chann LAGADEC, Researcher CRCN, Inserm
Research field: Molecular mechanisms of cell reprogramming and its implication in disease progression.
Key words: CSC, cell plasticity, reprogramming, tumor resistance, tumor dormancy, metastatic development.


Dr Samuel MEIGNAN, Researcher, Centre Oscar Lambret
Research field: Study of mechanisms involved in diffuse intrinsic pontine gliomas resistance to chemo and radiotherapy.
Key words: DIPG, pediatric glioma, resistance to treatment, epigenetics, drug repositioning.


Dr Juliette BEAUJOT, pathologist, Centre Oscar Lambret, MD


Pr Dominique CHEVALIER, head ans neck surgeon, PU PH, CHU of Lille


Dr Isabelle FERRY, pediatric Oncologist, Centre Oscar Lambret, MD


Dr Karine HANNEBICQUE, breast surgeon, Centre Oscar Lambret, MD


Dr François MOUAWAD, head and neck surgeon, CHU of Lille, MD-PhD


Dr Bénédicte RYSMAN, head and neck surgeon, CHU of Lille, MD



Mélanie ARCICASA, Research Technician, Centre Oscar Lambret


Aurélien DISPOT, Engineer, Lille University


Christine BAL, Research Technician, Centre Oscar Lambret


Isabelle LEFEBVRE, Lille University Technician


Nicole LEMAHIEU, Research Technician, Centre Oscar Lambret


Julia PUIG, Engineer, University of Lille


Pamela VÖLKEL, Engineer, CNRS



Quentin BAILLEUL (Y3, PhD student)
Impact of H3.3K27M mutation on pediatric high-grade gliomas resistance to treatments.


Clément LECERF (Y3, PhD student)
Role of non-conding RNA H19 in genetic instability.


Pauline TRÉBULLE (Y3, PhD student INRA Jouy-en-Josas)
Multiscale modeling of biological networks for the metabolic engineering of a biotechnological chassis.


Marie DENOULET (Y2, PhD student)
Epigenetic mechanisms regulating the reprogramming of non-CSCs into CSCs in breast cancer.


Sarah TROUVILLIEZ (Y2, PhD student)
Proteomic analysis of NGF response in breast cancer.


Marie WINTER (Y2, PhD student)
Triple negative breast cancer: mechanisms of escape and recurrence after chemotherapy.


Meng XIANGYU (Y2, Institut Curie PhD student)
Towards personalized medicine for basal subtype bladder cancers, use of the networks involved.


Mathilde BRULÉ (Y1, PhD student)
Role of the redox balance in the reprogramming of non-CSCs into CSCs after ionizing irradiation.


Evodie PEPERSTRAETE (Y1, PhD student)
Relative contribution of non-coding RNA H19 and miR-675 in breast tumorigenesis.


Ludivine RABY (Y1, PhD student)
Polycomb repression and zebrafish model in cancerology.


Our project is based on two models, breast cancer and pediatric brain tumors.


Breast cancer cells plasticity and metastasis

One of the approaches developed by our team is the study of the molecular mechanisms involved in cell reprogramming that can be targeted to improve the effectiveness of treatments. We were thus able to highlight the role of pro-inflammatory cytokines, released after radiotherapy, in the reprogramming of breast non cancer stem cells into cancer stem cells (CSCs). Thus, neutralization of these cytokines reduces the post-treatment CSC enrichment and prolongs the lifespan in a mouse model. In parallel, we demonstrated that the expression of cytokines and their receptors could be used as predictive markers of a response to radiotherapy in a cohort of 10,000 patients.

We are currently interested in the epigenetic mechanisms involved in the re-expression of “stemness” proteins and in the implication of the phenotypic reprogramming in tumor dormancy and metastatic development, in collaboration with physicists from IEMN and LIMMS. We will also use home-made new molecular tools, cellular and animal models to monitor and to characterize CSCs and the reprogramming process. For example, we have established persistent triple negative breast cancer cell lines after treatment with chemotherapeutical agents in order to better understand the behaviors of persistent cancer cells during tumor dormancy and metastatic development. In addition, we have combined C3(1)Tag transgenic mice, reproducing breast tumorigenesis, with transgenic mice expressing the CSC marker s-SHIP fused with GFP, in order to isolate and characterize stem cells during breast tumorigenesis and to dissect molecular mechanisms involved in the control of stemness, cell phenotype plasticity and tumor resistance to treatments.

In addition to these aspects, our team is a pioneer in the demonstration of the role of NGF (Nerve Growth Factor) and its precursor, proNGF in breast cancer development. Our recognized expertise in the field of membrane receptors and their downstream signaling pathways has enabled us to demonstrate recently that NGF induces the formation of TrkA/CD44 receptor complexes, while proNGF induces the formation of TrkA/EphA2 complexes. Concomitant inhibition of TrkA and EphA2 has been shown to decrease cerebral metastatic formation. Our goal is therefore to study the underlying mechanisms of receptor complexes formation and their downstream signaling pathways in order to target them to reduce/prevent metastasis.

We have been the first to demonstrate the role and mechanisms of action of the long non-coding RNA H19, and of the miR-675 it generates, in breast cancer. Currently, we are interested in different mechanisms of action of lncRNA such as the “miRNA sponge” effect, the “scaffold” effect of protein complex and the targeting of chromatin-modifying complex on DNA. In addition, we are studying the role of H19 and its miR in the various phenotypes associated with the emergence and development of breast cancer, including cell proliferation, survival, migration, invasion, EMT and metastasis formation. These studies are carried out in breast cancer cell lines in vitro as well as the C3(1)Tag murine tumorigenesis model and in zebrafish model.


Epigenetics and resistance to treatments for pediatric gliomas

Resistance to classical treatments and the associated mechanisms are also major issues in the management of pediatric diffuse gliomas located in the brainstem. However, the very particular profile and the dramatic prognosis of these tumors require their own investigation. In this context, and based on the shared molecular tools and knowledge in our team, we are carrying out work specifically on the resistance to treatments of DIPG (Diffuse Intrinsic Pontine Glioma), and this through 3 complementary in vitro approaches: the study of the H3.3K27M mutation impact on resistance to treatments, the screening of compounds without a priori / repositioning of drugs, and the development of a “DIPG on a chip” microfluidic model.

In parallel with these in vitro approaches, we are developping innovative transgenic zebrafish models in this topic. The zebrafish is a vertebrate model increasingly used in biomedical research because of the ease and low costs of its breeding, the wide possibilities of manipulation of its genome and the relative transparency of its embryo which allows imaging with the cellular resolution. Using genome editing and transgenesis, the team generates zebrafish lines with genetic and epigenetic alterations found in human cancers. These models allow us to better understand the mechanisms involved in tumorigenesis, including pediatric gliomas, and are used to study the effectiveness of different therapeutic approaches. Xenotransplantation of human tumor cells into two-day zebrafish embryos also allows us to analyze tumor formation, its evolution and to assess the effect of anticancer molecules in vivo.


Inference, interrogation and engineering of regulatory networksn

In addition to these different experimental biology approaches, the team includes a bioinformatics group the objective of which is to study regulatory networks (signaling pathways, transcriptional and metabolic regulation), an approach that has become of major interest for the understanding and management of cancers. Our aim here is to rationalize the study of regulatory networks through a predictive cycle, called “I3-BioNet”, composed of three modules: inference, interrogation, genomic and metabolic engineering of regulatory networks. We are thus developing multidisciplinary projects applied to the integrative analysis of regulatory networks (signaling pathways, transcriptional regulatory pathways) controlling differentiation, heterogeneity of the disease, cell plasticity and reprogramming. Our project benefits from funding of european and national research foundations, and the tools and models developed are systematically made available to the scientific community.


Publications 2020-2015



El Ati, Z., Machfar, H., Boussafa, H., Ati, N., Sioud, O. B. O., Zantour, B., … & Elati, M. (2020). Metabolic syndrome, malnutrition, and its associations with cardiovascular and all-cause mortality in hemodialysis patients: Follow-up for three years. Saudi Journal of Kidney Diseases and Transplantation, 31(1), 129.

Dhifli, W., Karabadji, N. E. I., & Elati, M. (2020). Evolutionary mining of skyline clusters of attributed graph data. Information Sciences, 509, 501-514.

Rogez B, Pascal Q, Bobillier A, Machuron F, Toillon RA, Tierny D, Chopin V, Le Bourhis X. Expression and Prognostic Significance of Neurotrophins and Their Receptors in Canine Mammary Tumors. Vet Pathol. 2020 Jul;57(4):507-519. doi: 10.1177/0300985820921813. Epub 2020 Apr 30. PMID: 32351171

Peperstraete E, Lecerf C, Collette J, Vennin C, Raby L, Völkel P, Angrand PO, Winter M, Bertucci F, Finetti P, Lagadec C, Meignan S, Bourette RP, Le Bourhis X , Adriaenssens E. Enhancement ofBreast Cancer Cell Aggressiveness by lncRNA H19 and its Mir-675 Derivative: Insight into Shared and Different Actions. Cancers (Basel). 2020 Jun 29;12(7):1730. doi: 10.3390/cancers12071730.PMID: 32610610

Raby L, Völkel P, Le Bourhis X, Angrand PO. The Polycomb Orthologues in Teleost Fishes and Their Expression in the Zebrafish Model. Genes (Basel). 2020 Mar 27;11(4):362. doi: 10.3390/genes11040362.


Bidan N, Bailleul-Dubois J, Duval J, Winter M, Denoulet M, Hannebicque K, El-Sayed IY, Ginestier C, Forissier V, Charafe-Jauffret E, Macario M, Matsunaga YT, Meignan S, Anquez F, Julien S, Bonnefond A, Derhourhi M, Le Bourhis X, Lagadec C. Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. Proteomics. 2019 Nov;19(21-22):e1800454. doi: 10.1002/pmic.201800454.

Tian L, Truong MJ, Lagadec C, Adriaenssens E, Bouchaert E, Bauderlique-Le Roy H, Figeac M, Le Bourhis X, Bourette RP. s-SHIP Promoter Expression Identifies Mouse Mammary Cancer Stem Cells. Stem Cell Reports. 2019 Jul 9;13(1):10-20. doi: 10.1016/j.stemcr.2019.05.013.

Völkel P, Bary A, Raby L, Chapart A, Dupret B, Le Bourhis X, Angrand PO. Ezh1 arises from Ezh2 gene duplication but its function is not required for zebrafish development. Sci Rep. 2019 Mar 13;9(1):4319. doi: 10.1038/s41598-019-40738-9.

Lévêque R, Corbet C, Aubert L, Guilbert M, Lagadec C, Adriaenssens E, Duval J, Finetti P, Birnbaum D, Magné N, Chopin V, Bertucci F, Le Bourhis X, Toillon RA. ProNGF increases breast tumor aggressiveness through functional association of TrkA with EphA2. Cancer Lett. 2019 May 1;449:196-206. doi: 10.1016/j.canlet.2019.02.019.

Dhifli, J. Puig, M. Elati. Latent network-based representations for large-scale gene expression data analysis. BMC Bioinformatics, 2019 Feb 4;19(Suppl 13):466. doi: 10.1186/s12859-018-2481-y.


Takayama Y, Perret G, Kumemura M, Ataka M, Meignan S, Karsten SL, Fujita H, Collard D, Lagadec C and Tarhan MC. Developing a MEMS Device with Built-in Microfluidics for Biophysical Single Cell Characterization. Micromachines, In press.

Dupret B, Völkel P, Follet P, Le Bourhis X, Angrand PO. Combining genotypic and phenotypic analyses on single mutant zebrafish larvae. MethodsX. 2018, 5: 244-256.

Tian L, Zhao Y, Truong MJ, Lagadec, C Bourette RP. Synuclein gamma expression enhances radiation resistance of breast cancer cells. Oncotarget. 2018, 9:27435-47.

Rogez B, Pascal Q, Bobillier A, Machuron F, Lagadec C, Tierny D, Le Bourhis X, Chopin V. CD44 and CD24 Expression and Prognostic Significance in Canine Mammary Tumors. Vet Pathol. 2019 May;56(3):377-388. doi: 10.1177/0300985818813653.

Dupret B, Völkel P, Vennin C, Toillon RA, Le Bourhis X, Angrand PO. The histone lysine methyltransferase Ezh2 is required for maintenance of the intestine integrity and for caudal fin regeneration in zebrafish. Biochim Biophys Acta Gene Regul Mech. 2017 Oct;1860(10):1079-1093. doi: 10.1016/j.bbagrm.2017.08.011.

Lopez-Rincon, A. Tonda, M. Elati, O. Schwander, B. Piwowarski, P. Gallinari Evolutionary Optimization of Convolutional Neural Networks for Cancer miRNA Biomarkers Classification. Applied Soft Computing : vol. 65, pp. 91-100, ( Elsevier), 2018.

E.I. Karabadji, S. Beldjoudi, H. Seridi, S. Aridhi, W. Dhifli. Improving Memory Based User Collaborative Filtering with Evolutionary Multi-Objective Optimization. Expert Systems With Applications 98: 153–165, 2018.

Singh V, Ostaszewski M, Kalliolias GD, Chiocchia G, Olaso R, Petit-Teixeira E, Helikar T, Niarakis A*, Computational systems biology approach for the study of Rheumatoid Arthritis: from a molecular map to a dynamical model, Genomics and Computational Biology, 2018, 4 (1): e10050.

Luo XW, Du XQ, Li JL, Liu XP, Meng XY*. Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis. Cancer Management and Research, 2018, 10: 2817-2823.


Dupret B, Völkel P, Vennin C, Toillon RA, Le Bourhis X, Angrand PO. The histone lysine methyltransferase Ezh2 is required for maintenance of the intestine integrity and for caudal fin regeneration in zebrafish. Biochim Biophys Acta. 2017,1860: 1079-1093. IF: 5,3

Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017, 385: 198-206.

Trébulle, J-M Nicaud, Ch. Leplat, M. Elati*, Inference and interrogation of a coregulatory network in the context of lipid accumulation in Yarrowia lipolytica. Nature npj Systems Biology and Applications (2017): Aug 11;3:21. eCollection 2017.

Trejo Banos, P. Tebulle, M. Elati* Integrating transcriptional activity in genome-scale models of metabolism, BMC Systems Biology (2017): 11(Suppl 7):134.

Dhifli, S. Aridhi, E. M. Nguifo. MR-SimLab: Scalable Subgraph Selection with Label Similarity for Big Data. Information Systems (Elsevier) 69: 155–163, 2017.

Dhifli, N. O. Da Costa, M. Elati* An Evolutionary Schema for Mining Skyline Clusters of Attributed Graph Data, IEEE Congress on Evolutionary Computation (2017): pp. 2102-2109

K. Saha, A. Katebi, W. Dhifli, M. Al Hassan. Discovery of Functional Motifs from the Interface Region of Oligomeric Proteins using Frequent Subgraph Mining. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019 Sep-Oct;16(5):1537-1549. doi: 10.1109/TCBB.2017.2756879.


Dupret B, Völkel P, Le Bourhis X, Angrand PO. The Polycomb Group protein Pcgf1 is dispensable in zebrafish but involved in early growth and aging. PLoS ONE 2016; 11: e0158700.

Brocqueville G, Chmelar RS, Bauderlique-Le Roy H, Deruy E, Tian L, Vessella RL, Greenberg NM, Rohrschneider LR, Bourette RP. s-SHIP expression identifies a subset of murine basal prostate cells as neonatal stem cells. Oncotarget. 2016, 7, 29228-44.

Bouyioukos, F. Bucchini, M. Elati, F. Képès. GREAT: a web portal for Genome Regulatory Architecture Tools. Nucleic Acids Research, gkw384, 2016.

Bouyioukos, M. Elati. Analysis tools for the interplay between genome layout and regulation. BMC Bioinformatics, 17 (5), 407, 2016.

Dhifli, A. B. Diallo. ProtNN: Fast and Accurate Protein 3D-Structure Classification in Structural and Topological Space. BMC BioData Mining 9 (1): 1-17, 2016.

Njah, S. Jamoussi, W. Mahdi and M. Elati. A Bayesian approach to construct context-specific gene ontology. Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), IEEE, pp1-6, 2016.


Tomellini E, Touil Y, Lagadec C, Julien S, Ostyn P, Ziental-Gelus N, Meignan S, Lengrand J, Adriaenssens E, Polakowska R, Le Bourhis X. Nerve growth factor and proNGF simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment. Stem Cells. 2015, 33, 342-53.

Bauderlique-Le Roy H, Vennin C, Brocqueville G, Spruyt N, Adriaenssens E, Bourette RP. Enrichment of Human Stem-Like Prostate Cells with s-SHIP Promoter Activity Uncovers a Role in Stemness for the Long Noncoding RNA H19. Stem Cells Dev. 2015, 24: 1252-62.

Aubert L, Guilbert M, Corbet C, Génot E, Adriaenssens E, Chassat T, Bertucci F, Daubon T, Magné N, Le Bourhis X, Toillon RA. NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib. 2015, 6: 9807-19.

Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, Chassat T, Bourette RP, Le Bourhis X, Adriaenssens E. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015, 6: 29209-23.

Nicolle, F. Radvanyi, and M. Elati, CoRegNet: reconstruction and integrated analysis of co-regulatory networks, Bioinformatics, btv305, 2015.



Raby L, Völkel P, Le Bourhis X, Angrand PO. The Polycomb Orthologues in Teleost Fishes and Their Expression in the Zebrafish Model. Genes (Basel). 2020 Mar 27;11(4):362. doi: 10.3390/genes11040362.

Raby L, Völkel P, Le Bourhis X, Angrand PO. Genetic Engineering of Zebrafish in Cancer Research. Cancers (Basel). 2020 Aug 4;12(8):2168. doi: 10.3390/cancers12082168.


Raby L, Völkel P, Le Bourhis X, Angrand PO. [Cancer cell transplantation in zebrafish: From translational research to personalized medicine]. Bull Cancer. 2019 Aug 26. pii: S0007-4551(19)30269-3.

Lecerf C, Le Bourhis X, Adriaenssens E. The long non-coding RNA H19: an active player with multiple facets to sustain the hallmarks of cancer. Cell Mol Life Sci. 2019 Dec;76(23):4673-4687. doi: 10.1007/s00018-019-03240-z.


Vennin C, Adriaenssens E. Long non-coding RNA and messenger RNA-the meeting of two worlds. J Thorac Dis. 2018, 10: 544-546.

Völkel P, Dupret B, Le Bourhis X, Angrand PO. Le modèle poisson zèbre dans la lutte contre le cancer. Med Sci. 2018, 34: 345-53.

Lagadec C, Toillon RA, Le Bourhis X. WhatsApp com between glioma stem cells and differentiated cells to sustain tumor growth. Stem Cell Investig. 2018 Sep 7;5:28. doi: 10.21037/sci.2018.08.04.

Dupret B, Völkel P, Follet P, Le Bourhis X, Angrand PO. Combining genotypic and phenotypic analyses on single mutant zebrafish larvae. MethodsX. 2018 Mar 14;5:244-256. doi: 10.1016/j.mex.2018.03.002.

Collette J, Le Bourhis X, Adriaenssens E. Regulation of Human Breast Cancer by the Long Non-Coding RNA H19. Int J Mol Sci. 2017 Nov 3;18(11). pii: E2319. doi: 10.3390/ijms18112319.

Ostaszewski, M., Gebel, S., Kuperstein, I., Mazein, A., Zinovyev, A., Dogrusoz U., Hasenauer J., Fleming R., Le Novere N., Gawron P., Ligon T., Niarakis A., Nickerson D., Weindl D., Balling R., Barillot E., Auffray C., Schneider, R. (2018). Community-driven roadmap for integrated disease maps. Briefings in Bioinformatics, bby024, (2018)


Hochart A, Leblond P, Le Bourhis X, Meignan S, Tulasne D. MET receptor inhibition: Hope against resistance to targeted therapies? Bull Cancer. 2017, 104:157-166. IF: 0.9 ; citations=3

Collette J, Le Bourhis X, Adriaenssens E. Regulation of Human breast cancer by the long non-coding RNA H19. Int. J. Mol. Sci. 2017, 18: 2319.

Bailleul-Dubois J, Bidan N, Le Bourhis X, Lagadec C. Effet de la radiothérapie sur les cellules souches cancéreuses de cancer de sein: résistance, reprogrammation et traitements. Oncologie. 2017, 19 :77-80.

Chopin V, Lagadec C, Toillon RA, Le Bourhis X. Neurotrophin signaling in cancer stem cells. Cell Mol Life Sci. 2016, 73:1859-70.


Rysman B, Mouawad F, Gros A, D. Chevalier D, Meignan S. HER3 receptor, a key role in head and neck squamous cell carcinomas. Head and Neck 2016, 38 Suppl 1:E2412-8.


Völkel P, Dupret B, Le Bourhis X, Angrand PO. Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res 2015, 7: 175-93. IF: 2.8 ; citations=61

Angrand PO, Vennin C, Le Bourhis X, Adriaenssens E. The role of long non-coding RNAs in genome formatting and expression. Front Genet. 2015, 6: 165.



Hochart A, Escande F, Rocourt N, Grill J, Koubi-Pick V, Beaujot J, Meignan S, Vinchon M, Maurage CA, Leblond P. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma. Ann Clin Transl Neurol. 2015, 2:439-43.

Abecassis J, Albert S, Atallah E…Meignan S, …Actualités et innovations en cancérologie des voies aérodigestives supérieures. 2015 report of Société Française d’ORL et de chirurgie cervivo-faciale. Par Jean Lacau Saint Guily & Emile Reyt (Edition Elsevier Masson).



Coutant, A., Roper, K., Trejo-Banos, D., Bouthinon, D., Carpenter, M., Grzebyta, Santini, G., Soldano, H., Elati, M. , Ramon, J., Rouveirol, C., Saldatova, L., Ross, K. (2019). Closed-loop cycles of experiment design, execution, and learning accelerate systems biology model development in yeast. Proceedings of the National Academy of Sciences (PNAS), 116(36), 18142-18147.

Champion, M., Chiquet, J., Neuvial, P., Elati, M., Radvanyi, F., & Birmelé, E. (2020). Identification of Deregulated Transcription Factors Involved in Specific Bladder Cancer Subtypes. Journal of Bioinformatics and Computational Biology.

Zerrouk, N., Miagoux, Q., Dispot, A., Elati, M., & Niarakis, A. (2020). Identification of putative master regulators in rheumatoid arthritis synovial fibroblasts using gene expression data and network inference. Scientific reports, 10(1), 1-13.

Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP, Mysiorek C. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020 Jun 2;17(1):37. doi: 10.1186/s12987-020-00198-0.
PMID: 32487241

Trzaska C, Amand S, Bailly C, Leroy C, Marchand V, Duvernois-Berthet E, Saliou JM, Benhabiles H, Werkmeister E, Chassat T, Guilbert R, Hannebique D, Mouray A, Copin MC, Moreau PA, Adriaenssens E, Kulozik A, Westhof E, Tulasne D, Motorin Y, Rebuffat S, Lejeune F. 2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. Nat Commun. 2020 Mar 20;11(1):1509. doi: 10.1038/s41467-020-15140-z.PMID: 32198346.


Tonolo F, Salmain M, Scalcon V, Top S, Pigeon P, Folda A, Caron B, McGlinchey MJ, Toillon RA, Bindoli A, Jaouen G, Vessières A, Rigobello MP. Small Structural Differences between Two Ferrocenyl Diphenols Determine Large Discrepancies of Reactivity and Biological Effects. ChemMedChem. 2019 Oct 4;14(19):1717-1726. doi: 10.1002/cmdc.201900430.

Azkanaz M, Rodríguez López A, de Boer B, Huiting W, Angrand PO, Vellenga E, Kampinga HH, Bergink S, Martens JH, Schuringa JJ, van den Boom V. Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock. Elife. 2019 Jun 14;8. pii: e45205. doi: 10.7554/eLife.45205.

Grolez GP, Hammadi M, Barras A, Gordienko D, Slomianny C, Völkel P, Angrand PO, Pinault M, Guimaraes C, Potier-Cartereau M, Prevarskaya N, Boukherroub R, Gkika D. Encapsulation of a TRPM8 Agonist, WS12, in Lipid Nanocapsules Potentiates PC3 Prostate Cancer Cell Migration Inhibition through Channel Activation. Sci Rep. 2019 May 28;9(1):7926. doi: 10.1038/s41598-019-44452-4.

Saidi, W. Dhifli , M. Maddouri, E. M. Nguifo. Efficiently mining recurrent substructures from protein 3D-structure graphs. Journal of Computational Biology J Comput Biol. 2019 Jun;26(6):561-571. doi: 10.1089/cmb.2018.0171.


Bliman D, Demeunynck, M, Leblond P, Meignan, S, Baussanne I, Fort S. Enzymatically Activated Glyco-Prodrugs of Doxorubicin Synthesized by a Catalysis-Free Diels-Alder Reaction. Bioconjugate Chemistry. In press.

El Hajj J, Nguyen E, Liu Q, Bouyer C, Adriaenssens E, Hilal G, Ségal-Bendirdjian E. Telomerase regulation by the long non-coding RNA H19 in human acute promyelocytic leukemia cells. Mol Cancer. 2018, 17:85.

Li JL, Fan GY, Liu YJ, Zeng ZH, Huang JJ, Yang ZM, Meng XY. Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials. Front Pharmacol. 2018 Apr 30;9:430. doi: 10.3389/fphar.2018.00430. eCollection 2018.

Luo XW, Du XQ, Li JL, Liu XP, Meng XY. Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis. Cancer Management and Research, 2018, 10: 2817-2823.

Park, Y. K., Korpys, P., Kubiak, M., Celinska, E., Soudier, P., Trébulle, P., … & Nicaud, J. M. (2018). Engineering the architecture of erythritol-inducible promoters for regulated and enhanced gene expression in Yarrowia lipolytica. FEMS yeast research.


Kondratskyi A, Kondratska K, Vanden Abeele F, Gordienko D, Dubois C, Toillon RA, Slomianny C, Lemière S, Delcourt P, Dewailly E, Skryma R, Biot C, Prevarskaya N. Ferroquine, the next generation antimalarial drug, has antitumor activity. Sci Rep. 2017, 7:15896. IF: 4.3 ; citation=1

Benhabiles H, Gonzalez-Hilarion S, Amand S, Bailly C, Prévotat A, Reix P, Hubert D, Adriaenssens E, Rebuffat S, Tulasne D, Lejeune F. Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases. PLoS ONE. 2017, 12: e0187930.


Steenackers A, Olivier-Van Stichelen S, Baldini SF, Dehennaut V, Toillon RA, Le Bourhis X, El Yazidi-Belkoura I, Lefebvre T. Silencing the Nucleocytoplasmic O-GlcNAc Transferase Reduces Proliferation, Adhesion, and Migration of Cancer and Fetal Human Colon Cell Lines. Front Endocrinol (Lausanne). 2016, 7:46.

Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP. F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. Cancer Lett. 2016, 1;370:10-8.

Wambang N, Schifano-Faux N, Aillerie A, Baldeyrou B, Jacquet C, Bal-Mahieu C, Bousquet T, Pellegrini S, Ndifon PT, Meignan S, Goossens JF, Lansiaux A, Pélinski L. Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors. Bioorg Med Chem. 2016, 15 :651-60.

Woodman N, Pinder SE, Tajadura V, Le Bourhis X, Gillett C, Delannoy P, Burchell JM, Julien S. Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer. Int J Oncol. 2016, 49:265-75.

E.I. Karabadji, H. Seridi, F. Bousetouane, W. Dhifli, S. Aridhi. An Evolutionary Scheme for Decision Tree Construction. Knowledge-Based Systems (Elsevier) 2016. 119: 166-177, 2017


Simonneau C, Leclercq B, Mougel A, Adriaenssens E, Paquet C, Raibaut L, Ollivier N, Drobecq H, Marcoux J, Cianferani S, Tulasne D, de Jonge H, Melnyk O, Vicogne J. Semi-synthesis of a HGF/SF kringle one (K1) domain scaffold generates a potent in vivo MET receptor agonist. Chem Sci. 2015, 6: 2110-21.

Rahier NJ, Molinier N, Long C, Deshmukh SK, Kate AS, Ranadive P, Verekar SA, Jiotode M, Lavhale RR, Tokdar P, Balakrishnan A, Meignan S, Robichon C, Gomes B, Aussagues Y, Samson A, Sautel F, Bailly C. Anticancer activity of koningic acid and semisynthetic derivatives. Bioorg Med Chem. 2015, 23:3712-21.

Picchetti, J. Chiquet, M. Elati, P. Neuvial, R. Nicolle, E. Birmelé. A model for gene deregulation detection using expression data, BMC Syst Biol. 2015;9 Suppl 6:S6. doi: 10.1186/1752-0509-9-S6-S6.

Talleh, G. Nuel, E. Bischoff, A. Aubouy, M. Elati, et al. Gene transcriptomic pattern of Plasmodium falciparum in children with cerebral malaria and asymptomatic carriers, PlosOne, 9: e114401, 2015

On-going theses

  • Quentin Baille (Y3 in 2020 – Thesis director: Samuel Meignan)
  • Clément Lecerf (Y3 in 2020 – Thesis director: Eric Adriaenssens)
  • Marie Denoulet (Y3 in 2020 – Thesis director: Chann Lagadec) 
  • Sarah Trouvilliez (Y3 in 2020 – Thesis director: Robert-Alain Toillon) 
  • Marie Winter (Y3 in 2020 – Thesis director: Xuefen Le Bourhis) 
  • Meng Xiangyu (Y3 in 2020 – Thesis director: Mohamed Elati) 
  • Mathilde Brulé (Y2 in 2020 – Thesis director: Chann Lagadec)
  • Evodie Peperstraete (Y2 in 2020 – Thesis director: Eric Adriaenssens)
  • Ludivine Raby (Y2 in 2020 – Thesis director: Pierre-Olivier Angrand)
  • Andria Rakotomalala (Y1 in 2020 – Thesis director : Samuel Meignan)
  • Julien Cicero (Y1 in 2020 – Thesis director : Robert-Alain Toillon)
  • Amina NAIT ELDJOUDI (Y1 in 2020-Thesis director : Xuefen Le Bourhis)

Defended theses


  • BAILLEUL Quentin, «Etude de l’impact de la mutation H3.3K27M sur le phénotype agressif et résistant de lignées cellulaires de gliome pédiatrique », Directeur : Samuel Meignan
  • LECERF Clément, « Instabilité génomique et mécanismes moléculaires régulés par le long ARN non codant H19 dans les cancers du sein. », Directeur : Eric Adriaenssens


  • COLETTE Jordan, « Étude des mécanismes impliqués dans la régulation de la tumorigenèse mammaire par le long ARN non codant H19 », Directeur : Eric Adriaenssens
  • LEVEQUE Romain, « Plasticité des réseaux de récepteurs membranaires dans la signalisation du NGF et de son précurseur dans les cancers du sein », Directeurs : Robert-Alain Toillon/Dominique Chevalier
  • BIDAN Nadège, « Développement d’un système rapporteur de la plasticité des cellules cancéreuses du sein », Directeur : Chann Lagadec
  • TREBULLE Pauline, « Modélisation multi-échelles de réseaux biologiques pour l’ingénierie métabolique d’un châssis biotechnologique », Directeurs :  Mohamed Elati/Jean-Marc Nicaud


  • BAILLEUL Justine, « Étude des mécanismes impliqués dans la reprogrammation de cellules cancéreuses non-souches en cellules souches cancéreuses induite par les radiations ionisantes dans le cancer du sein », Directeurs : Chann Lagadec/Xuefen Le Bourhis
  • ROGER Bernadette, « Effets des neurotrophines dans l’enrichissement des cellules souches de cancer du sein et étude translationnelle dans le modèle canin », Directrice : Xuefen Le Bourhis
  • TIAN Lu, « Isolement et caractérisation de cellules souches cancéreuses dans un modèle murin de tumorigénèse mammaire », Directeur : Roland Bourette


  • DUPRET Barbara, « Étude du rôle des protéines Polycomb Pcgf1 et Ezh2 chez le poisson zèbre Danio rerio », Directeur : Pierre-Olivier Angrand


  • VENNIN Constance, « Contribution et rôles dans la tumorigenèse des ARN non codants transcrits au locus H19/IGF2 : H19 et 91H », Directeur : Eric Adriaenssens


  • GUILBERT Matthieu, « Impact de la transactivation des récepteurs membranaires par le (pro)NGF dans les cancers », Directeur : Robert-Alain Toillon
  • NICOLLE Remy, « Regulatory networks driving bladder cancer », Directeurs : Mohamed Elati/François Radvanyi